Literature DB >> 918850

Acute reversible renal failure following jejunoileal bypass for morbid obesity: a clinical and pathological (EM) study of a case.

S M Ehlers, Z Posalaky, R G Strate, F W Quattlebaum.   

Abstract

A patient who underwent jejunoileal bypass for morbid obesity developed servere renal failure associated with hyperoxaluria and renal oxalosis. Renal function improved and oxalate excretion decreased following hemodialysis and restoration of gastrointestinal continuity.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 918850

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


  6 in total

1.  Nephrolithiasis and nephrocalcinosis in rats with small bowel resection.

Authors:  R Corey O'Connor; Elaine M Worcester; Andrew P Evan; Shane Meehan; Dimitri Kuznetsov; Brett Laven; Andre' J Sommer; Sharon B Bledsoe; Joan H Parks; Fredric L Coe; Marc Grynpas; Glenn S Gerber
Journal:  Urol Res       Date:  2005-05

Review 2.  Surgical management of morbid obesity.

Authors:  S N Joffe
Journal:  Gut       Date:  1981-03       Impact factor: 23.059

3.  Oxalate nephropathy due to gastrointestinal disorders.

Authors:  H J Canos; G A Hogg; J R Jeffery
Journal:  Can Med Assoc J       Date:  1981-03-15       Impact factor: 8.262

4.  Calcium oxalate precipitation in urine following T.U.R. with glycine as irrigation fluid.

Authors:  C C Arvieux; J J Rambeaud; M C Denis; K Sirajedine; J P Alibeu; G Faure
Journal:  Urol Res       Date:  1987

5.  Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure.

Authors:  Samih H Nasr; Vivette D D'Agati; Samar M Said; Michael B Stokes; Maria V Largoza; Jai Radhakrishnan; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

Review 6.  Update on oxalate crystal disease.

Authors:  Elizabeth C Lorenz; Clement J Michet; Dawn S Milliner; John C Lieske
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.